Programmable mRNA Vaccines For Emerging Pathogens
Swapping only the encoded antigen sequence allows vaccine candidates against outbreak and pandemic pathogens with no licensed products to move from genome to clinic on a standing platform.
Developed mainly in: United StatesImpacting: North America, Europe and Middle East & Africa
Moderna has dosed the first participants in a Phase 1 study of mRNA-1469, an investigational vaccine against Bundibugyo ebolavirus, a filovirus strain with no currently approved vaccine. The trial is running in Canada under Health Canada authorisation, in partnership with CEPI, leveraging the same mRNA platform Moderna deployed for COVID-19.
This is one of 24 signals scored in our latest scan.
Track Them Free For 14 Days →Since we flagged this
First flagged
26 March 2026 · score 6.0/10
Corroborating sources since flagging
42
Latest signals
Tracked from 4 signals, each traced to its source.
- Moderna Launches Phase 1 Trial for mRNA Vaccine Targeting Bundibugyo Ebolavirus Strain
Newsroom · 21 Aug 2026
- Moderna Begins Phase 1 Trial of mRNA Vaccine Targeting Bundibugyo Ebolavirus Strain
Newswire · 13 Aug 2026
- mRNA and Next-Generation Vaccine Platforms for Pandemic Influenza Preparedness
Mdpi · 13 May 2026
1 more signal with dates, scores and flags in the full record. See them all →
In the full record
Evolution
Score over time, Score Jumps and how the evidence built up since the first signal.
Thesis
Paradigm Shift, Commercial Viability, signal strength and the driver of the change.
Why this innovation matters
The full analysis: what is shifting, who is affected and the second-order effects.
Forecasted Hypothesis
What would strengthen this innovation, and what would weaken it.
Exposure
Companies and publicly listed stock symbols linked to this innovation.
Every signal
Each signal with its date, score, flags and original source.
Open the full record free for 14 days → No card needed.
More in Biotech
Other innovations the engine is currently tracking in this industry.
- Virtual Trial Outcome Prediction7.0/ 10 · 2 signals
- Multi-Receptor Incretin Co-Agonists6.8/ 10 · 5 signals
- Programmable RNA And Expression Control7.7/ 10 · 3 signals
- Multivalent Seasonal Respiratory mRNA Vaccines6.5/ 10 · 2 signals
- Novel Food Approval Pathways For Cultivated Meat6.9/ 10 · 7 signals
- Clinical Genome-Editing Therapeutics7.8/ 10 · 6 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.